Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on Aug 29, 2011 10:54pm
239 Views
Post# 18991753

additional thoughts

additional thoughtsI just wanted to start off by saying that 4 yrs ago I sold shares of a company I had been holding for a period of time because I was not happy with some news that came out; 5 months later the stock doubled in price.
     Last night I had my Fantasy Football Draft and there are several Urologists that are in the league. It was late when I got home but I wanted to post because I was excited about several comments that were made about PCA3. They are all believers in the marker but as we know it is not the answer to every question related to prostate cancer. I think thats what comes into play here because the FDA is worried, even though GPRO submitted the test to be used with and elevated psa and a neg first biopsy, that Urologist's will use this test blindly. Meaning that they will simply use the test and not use it with other available resources to get the best picture of what is going on with their patients.
      I have followed many biotech companies for years and a slight delay due to the FDA reviewing additional information and cases is not at all uncommon. The studies are all there and GPRO did a good job keeping their claims very basic; but there again the FDA is looking past the intended use because they are well aware that patients and physicians are looking for the magic test to solve all problems. This is the best available test at this time and will only get better as additional markers are added, as studies published recently discuss, to assist the decision making process.
    I am looking forward to Diagnocure's call next week. I continue to believe that GPRO will try to acquire them, and I would not be surprised if it is not being discussed as I write this. We should not look at anything less that $3.00. If the panel meeting is scheduled for the first quarter of 2012, I would now expect, secondary to the additional time to review the data, a quick follow up approval by the FDA and again we will be on our way.
    After last nights discussion with the Urologists, I was looking to add between 25,000 to 50,000 shares to my current position. If it would have shown up at any point today on the ask, I would have hit it, only to be hit in the face a few hrs later with this delay. I have no idea how investors will react, I do know that buyers will be there waiting and I will be among the crowd.
Bullboard Posts